Physics-based US software specialist Schrödinger’s shares leapt nearly 14% to $22.25 on the back of news that it has entered ...

The price trend for Novartis (NVS) has been bearish lately and the stock has lost 5.1% over the past two weeks. However, the formation of a hammer chart pattern in its last trading session indicates ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...

As the COVID-19 pandemic clearly demonstrated, health is an integral part of Europe’s security. That principle underpinned a ...

https://www.tipranks.com/news/the-fly/schrodinger-announces-expanded-license-agreement-with-novartis Schrodinger (SDGR) today ...

In its recent earnings release for the third quarter of 2024, Schrödinger reported significant developments, including a new collaboration with Novartis, which will see an upfront payment of $150 ...

Atrial arrhythmias were found in 26% of patients with sickle cell disease (SCD), with a significant association with stroke history. Early detection and treatment of atrial arrhythmias may help ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

and Novartis. StudyFinds publishes digestible, agenda-free, transparent research summaries that are intended to inform the ...

Schrödinger (NASDAQ:SDGR) shares traded higher on Tuesday despite reporting lower-than-expected Q3 2024 financials after the ...

Alcon, whose biggest market is the U.S. making up nearly a half of its revenue, said it expected annual net sales to grow by ...